diabegon

a polyherbal preparation with preventive effects during progression of diabetes induced by high-fructose feeding in rats; contains bitter gourd, chirayata, gudmar patra and others (complete list in first source)

Networked: 2 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Prasad, G B K S: 2 articles (01/2014 - 09/2007)
2.	Baghel, Usha Singh: 1 article (01/2014)
3.	Bisen, P S: 1 article (01/2014)
4.	Mahajan, Sunil: 1 article (01/2014)
5.	Mishra, Meerambika: 1 article (01/2014)
6.	Subramanian, Senthil S: 1 article (01/2014)
7.	Tiwari, Arvind: 1 article (01/2014)
8.	Yadav, Dhananjay: 1 article (01/2014)
9.	Jain, Shalini: 1 article (09/2007)
10.	Yadav, Hariom: 1 article (09/2007)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 01/01/2014 - "Our study suggests that diabegon could be included as a preventive treatment in metabolic syndrome subjects with type 2 diabetes especially for long term treatment as it efficiently shows anti-hyperglycemic and anti-lipidemic effects with no adverse impacts on the liver and kidney." 01/01/2014 - "Anti-hyperglycemic and anti-hyperlipidemic potential of a polyherbal preparation "Diabegon" in metabolic syndrome subject with type 2 diabetes." 01/01/2014 - "In the present study, "Diabegon" a poly-herbal preparation, with hypoglycemic activity, was evaluated for its preventive effect in metabolic syndrome subjects with type 2 diabetes and also to reveal its side effects, on liver and kidney. " 09/01/2007 - "In the present study, the polyherbal preparation diabegon, containing 18 plant extracts with hypoglycemic activity, was evaluated for its preventive effect during progression of type 2 diabetes in high-fructose-diet-fed rats. "
2.	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/01/2014 - "Our study suggests that diabegon could be included as a preventive treatment in metabolic syndrome subjects with type 2 diabetes especially for long term treatment as it efficiently shows anti-hyperglycemic and anti-lipidemic effects with no adverse impacts on the liver and kidney." 01/01/2014 - "Anti-hyperglycemic and anti-hyperlipidemic potential of a polyherbal preparation "Diabegon" in metabolic syndrome subject with type 2 diabetes." 01/01/2014 - "In the present study, "Diabegon" a poly-herbal preparation, with hypoglycemic activity, was evaluated for its preventive effect in metabolic syndrome subjects with type 2 diabetes and also to reveal its side effects, on liver and kidney. "
3.	Dyslipidemias (Dyslipidemia) 09/01/2007 - "The mechanism of action by which diabegon attenuates insulin resistance and dyslipidemia may be through induction of peroxisome proliferator-activated receptor-gamma and lipoprotein lipase activity in peripheral tissues (muscles). "
4.	Glucose Intolerance 09/01/2007 - "Oral administration of diabegon (100 mg/kg body weight) delayed development of glucose intolerance for 4 weeks in comparison with the diabetic control group, and the effect of diabegon was compared to that of the standard insulin sensitizer drug rosiglitazone. "
5.	Insulin Resistance 09/01/2007 - "The mechanism of action by which diabegon attenuates insulin resistance and dyslipidemia may be through induction of peroxisome proliferator-activated receptor-gamma and lipoprotein lipase activity in peripheral tissues (muscles). "

Related Drugs and Biologics

1.	Hypoglycemic Agents (Hypoglycemics)
2.	Plant Preparations (Preparation, Plant)
3.	Plant Extracts
4.	Fructose
5.	PPAR gamma
6.	Lipoprotein Lipase (Diacylglycerol Lipase)
7.	Insulin (Novolin)
8.	Rosiglitazone (Avandia)

Related Therapies and Procedures

1.	Oral Administration